FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date
Bluebird bio eyes hattrick of gene therapy approvals, with a PDUFA date for sickle cell disease therapy lovo-cel set in December.
Bluebird bio eyes hattrick of gene therapy approvals, with a PDUFA date for sickle cell disease therapy lovo-cel set in December.
What's Your Reaction?
